Author: Dino Mustafić

June 29, 2020 Off

Adalvo waiting EC’s marketing authorization for Livogiva

By Dino Mustafić

Pharmaceutical company Adalvo today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Livogiva, indicated for use in postmenopausal women with osteoporosis who are at high risk of having bone fractures.

June 22, 2020 Off

Piramal Pharma buys solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.

By Dino Mustafić

Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary preclosing conditions.

June 16, 2020 Off

Sanofi invests in vaccine production in France, €490 million over five-years

By Dino Mustafić

Sanofi on Tuesday detailed plans investing in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks, aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.